4 Merger and Acquisitions Stock Stories Gaining Tuesday Traction
EBay Inc. (NASDAQ:EBAY): Current price $51.93
EBay says that it will purchase Shutl, a United Kingdom-based marketplace that employs a network of couriers to deliver local goods following an online purchase within a couple of hours. Financials of the transaction were not divulged. The company was founded by Tom Allason the founder and former Chief Executive of eCourier.co.uk in 2008.
Plains All American Pipeline, LP (NYSE: PAA): Current price $52.62
On Tuesday, Plains All American announced that it will merge with PAA Natural Gas Storage LP, whereby the latter will become a wholly-owned subsidiary of PAA by means of a unit-for-unit exchange. Through the terms of the deal, PAA Natural gas public unitholders will receive 0.445 common units of Plains per PAA common unit surrendered pursuant to the agreement, plus cash in lieu of any fractional common units of PAA otherwise issuable in the merger. The parties anticipate that the transaction should close in the latter half of the fourth quarter, and that the previously announced quarterly distribution of $0.3575 per PAA Natural Gas common unit payable to holders of record of such units on November 1 will be paid on November 14 as scheduled.
Cooper Tire & Rubber Co. (NYSE:CTB): Current price $24.40
Last week, Apollo Tyres Ltd. requested that a Delaware judge toss out a $2.5 billion takeover by Cooper, arguing that the firm has not kept its part of the bargain, and that the $35-a-share acquisition should be blocked. However, Delaware Chancery Court Judge Sam Glasscock III said Tuesday in a telephone hearing there is a need “to develop the facts,” and attorneys should “prepare for trial” if they can’t settle the case, thus denying Apollo’s request.
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT): Current price $1.85
Oxygen Biotherapeutics on Tuesday said it will acquire certain assets of the privately-held biopharmaceutical firm Phyxius Pharma, which is centered on the development and near-term commercialization of levosimendan, to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome, a significant unmet medical need addressing an approximate $600 million market in the United States. Through the terms, Oxygen Biotherapeutics will buy the exclusive rights to develop and commercialize levosimendan in North America, along with integrating three key Phyxius Pharma executives into its management team. The transaction is valued at roughly $4.8 million in stock as of October 18.